Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Drug approved by SMC for sight problems linked to diabetes

  • Comment

The Scottish Medicines Consortium has approved a new treatment option for visual impairment in patients with diabetic macular oedema.

Dexamethasone 0.7mg intravitreal implant and its applicator (Ozurdex) has been backed by the SMC for use by NHS Scotland.

The product is a biodegradable intravitreal implant that releases dexamethasone over an extended period of time to suppress inflammation.

The SMC recommendation applies to patients with oedema who are pseudophakic – have artificial lens implants due to cataract surgery – or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.

Diabetic macular oedema affects approximately 7% of people with diabetes.

The product’s manufacturer, Actavis, cited evidence that 50% of people with diabetic macular oedema do not respond to non-corticosteroid therapy, notably anti-VEGFs or laser.

It suggested that its treatment may also help “alleviate the burden” of oedema on patients, with fewer injections than existing options. Treatment with Ozurdex lasts at around five months on average, compared to anti-VEGF therapies that may require monthly injections.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.